Loading data for TRVI — first visit, this takes a few seconds.

알림

Trevi Therapeutics Inc. (TRVI)

NasdaqGM: TRVI · 실시간 가격 · USD

18.84

+0.36 (1.95%)

종가 기준: Aug 18, 2026, 3:59 PM

1.95% (1D)

매수호가	13.61
시가총액	2.68B
매출 (ttm)	n/a
순이익 (ttm)	-51.11M
베타	1.07
EPS (ttm)	-0.35
P/E (ttm)	n/a
선행 P/E	-32.65
P/B (ttm)	8.35
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

매도호가	23.73
거래량	1,746,728
평균 거래량 (20일)	2,068,576
시가	18.46
전일 종가	18.48
일중 범위	18.18 - 18.97
52주 범위	6.93 - 20.22
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

TRVI 소개

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatme...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 7, 2019

직원 수 34

상장 거래소 NasdaqGM

티커 TRVI

웹사이트 https://www.trevitherapeutics.com

전체 기업 정보

재무 실적

2025년 Trevi Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -42.76M로, -10.75% 감소했습니다.

재무제표

어닝 서프라이즈

Trevi Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.11 예상치 하회 0.00, 및 -22.22% 전년 대비 감소.

다음 실적 발표

Trevi Therapeutics Inc.의 실적 발표 예정일은 Nov 12, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · MarketBeat

Trevi Therapeutics Q2 Earnings Call Highlights

Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio,...

1주 전 · GuruFocus.com

Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ...

Trevi Therapeutics Inc (TRVI) reports progress in IPF and RCC trials, backed by $319 million in funding and a competitive edge following a rival's program exit.

1개월 전 · Insider Monkey

Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market

Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough...

2개월 전 · Motley Fool

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

3개월 전 · MarketBeat

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030

Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clin...

2 페이지 중 1

Trevi Therapeutics Inc. (TRVI)